DFTX vs. LRCX

Last updated Apr 1, 2026

Compare and contrast key facts about Definium Therapeutics, Inc (DFTX) and Lam Research Corporation (LRCX).

Performance

DFTX vs. LRCX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Definium Therapeutics, Inc (DFTX) and Lam Research Corporation (LRCX). The values are adjusted to include any dividend payments, if applicable.

DFTX vs. LRCX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
DFTX Definium Therapeutics, Inc	41.15%	92.39%	90.16%	66.36%	-76.86%
LRCX Lam Research Corporation	24.97%	139.16%	-6.84%	88.63%	5.24%

Fundamentals

Market Cap DFTX : $1.69B LRCX : $270.39B
EPS DFTX : -$2.12 LRCX : $4.89
PB Ratio DFTX : 5.08 LRCX : 26.65
Total Revenue (TTM) DFTX : $0.00 LRCX : $20.56B
Gross Profit (TTM) DFTX : $0.00 LRCX : $10.24B
EBITDA (TTM) DFTX : -$166.31M LRCX : $7.43B

Returns By Period

In the year-to-date period, DFTX achieves a 41.15% return, which is significantly higher than LRCX's 24.97% return.

DFTX

• 1D: 8.00%
• 1M: 8.31%
• YTD: 41.15%
• 6M: 60.31%
• 1Y: 223.08%
• 3Y*: 81.33%
• 5Y*: —
• 10Y*: —

LRCX

• 1D: 6.87%
• 1M: -8.54%
• YTD: 24.97%
• 6M: 60.02%
• 1Y: 196.05%
• 3Y*: 60.68%
• 5Y*: 28.66%
• 10Y*: 40.32%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

DFTX vs. LRCX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DFTX

DFTX Risk / Return Rank: 96
DFTX Sharpe Ratio Rank: 97
DFTX Sortino Ratio Rank: 94
DFTX Omega Ratio Rank: 91
DFTX Calmar Ratio Rank: 98
DFTX Martin Ratio Rank: 98

LRCX

LRCX Risk / Return Rank: 97
LRCX Sharpe Ratio Rank: 98
LRCX Sortino Ratio Rank: 95
LRCX Omega Ratio Rank: 95
LRCX Calmar Ratio Rank: 98
LRCX Martin Ratio Rank: 99

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DFTX vs. LRCX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Definium Therapeutics, Inc (DFTX) and Lam Research Corporation (LRCX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	DFTX	LRCX	Difference
Sharpe ratio Return per unit of total volatility	3.37	3.67	-0.30
Sortino ratio Return per unit of downside risk	3.50	3.58	-0.08
Omega ratio Gain probability vs. loss probability	1.42	1.50	-0.08
Calmar ratio Return relative to maximum drawdown	8.28	9.82	-1.53
Martin ratio Return relative to average drawdown	24.69	31.04	-6.35
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

DFTX vs. LRCX - Sharpe Ratio Comparison

The current DFTX Sharpe Ratio is 3.37, which is comparable to the LRCX Sharpe Ratio of 3.67. The chart below compares the historical Sharpe Ratios of DFTX and LRCX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	DFTX	LRCX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	3.37	3.67	-0.30
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.63	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.92	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.24	0.41	-0.17

Correlation

The correlation between DFTX and LRCX is 0.21, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

DFTX vs. LRCX - Dividend Comparison

DFTX has not paid dividends to shareholders, while LRCX's dividend yield for the trailing twelve months is around 0.47%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
DFTX Definium Therapeutics, Inc	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
LRCX Lam Research Corporation	0.47%	0.57%	1.19%	0.95%	1.53%	0.78%	1.04%	1.54%	2.79%	1.01%	1.28%	1.36%

Drawdowns

DFTX vs. LRCX - Drawdown Comparison

The maximum DFTX drawdown since its inception was -86.01%, roughly equal to the maximum LRCX drawdown of -87.90%. Use the drawdown chart below to compare losses from any high point for DFTX and LRCX.

Drawdown Indicators

	DFTX	LRCX	Difference
Max Drawdown Largest peak-to-trough decline	-86.01%	-87.90%	+1.89%
Max Drawdown (1Y) Largest decline over 1 year	-24.79%	-20.01%	-4.78%
Max Drawdown (5Y) Largest decline over 5 years	—	-56.39%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-56.39%	—
Current Drawdown Current decline from peak	-0.79%	-14.26%	+13.47%
Average Drawdown Average peak-to-trough decline	-53.79%	-28.31%	-25.48%
Ulcer Index Depth and duration of drawdowns from previous peaks	8.32%	6.33%	+1.99%

Volatility

DFTX vs. LRCX - Volatility Comparison

The current volatility for Definium Therapeutics, Inc (DFTX) is 15.17%, while Lam Research Corporation (LRCX) has a volatility of 20.58%. This indicates that DFTX experiences smaller price fluctuations and is considered to be less risky than LRCX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	DFTX	LRCX	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.17%	20.58%	-5.41%
Volatility (6M) Calculated over the trailing 6-month period	44.37%	40.44%	+3.93%
Volatility (1Y) Calculated over the trailing 1-year period	66.90%	53.75%	+13.15%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	85.26%	45.53%	+39.73%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	85.26%	44.09%	+41.17%

Financials